Cas:1019356-62-7 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline manufacturer & supplier

Chemical Name:8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline

CAS.NO:1019356-62-7

Synonyms:8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline

Molecular Formula:C₁₀H₉ClF₃N

Molecular Weight:235.63300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:12.03000

Exact Mass:235.03800

LogP:3.85490

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline Use and application,8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline technical grade,usp/ep/jp grade.

Related News: Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline manufacturer It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion. 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline supplier This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline vendor Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 8-chloro-5-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline factory In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.